Curated News
By: NewsRamp Editorial Staff
July 10, 2026

Greenland Mines Secures Australian Patent for Klotho Gene Therapy

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Greenland Mines' new Australian patent strengthens its Klotho gene therapy platform, potentially boosting its competitive edge in ALS treatment.
  • The patent covers gene therapy constructs, stem cells, and delivery systems for expressing human Klotho protein to treat neuromuscular diseases.
  • This advancement offers hope for ALS patients by targeting the root cause of neuromuscular degeneration through gene therapy.
  • Klotho protein, linked to longevity, is now being harnessed in gene therapy to fight ALS and other muscle disorders.

Impact - Why it Matters

This patent is crucial as it protects a promising gene therapy for ALS and other neuromuscular diseases, potentially offering new hope to patients. For investors, it strengthens Greenland Mines' IP portfolio, enhancing its valuation in both biotech and mining sectors. The development also underscores the growing convergence of advanced therapies and resource companies, positioning Greenland Mines as a unique player in the market.

Summary

Greenland Mines (NASDAQ: GRML) has announced a significant milestone in its biotechnology division, securing Australian Patent No. 2023252508 from IP Australia. This patent covers gene therapy technology exclusively licensed by the company for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent bolsters Greenland Mines' intellectual property for its Klotho-based therapeutic platform, including claims on gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. This development supports the advancement of the KLTO-202 program, which targets amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. The company's strategy involves building a multi-asset platform with exposure to rare earth materials and precious metals, while advancing its broader North Atlantic Critical Metals Corridor vision.

Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project, and Biotech, including the Klotho gene therapy platform. The patent strengthens the company's position in both sectors, offering potential treatments for devastating diseases like ALS. The company's newsroom provides the latest updates on GRML, and the full press release is available at https://nnw.fm/PVbbH. This news highlights the intersection of mining and biotechnology, showcasing Greenland Mines' innovative approach to creating value across multiple industries.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Greenland Mines Secures Australian Patent for Klotho Gene Therapy

blockchain registration record for this content.